2-bromo-6-methoxy-4-methylbenzaldehyde | 133129-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-6-methoxy-4-methylbenzaldehyde
• 英文别名: 2-bromo-6-hydroxy-4-methylbenzaldehyde
• CAS: 133129-29-0
• 化学式: C₉H₉BrO₂
• 分子量: 229.073
• InChiKey: WRAODBAWCVCFRE-UHFFFAOYSA-N

物化性质

• 沸点：
  301.1±37.0 °C(Predicted)
• 密度：
  1.453±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-6-methoxy-4-methylbenzaldehyde 在 palladium on activated charcoal 2,6-二甲基吡啶 、 四氧化锇 、 正丁基锂 、 N-甲基吲哚酮 、 氢气 、 叔丁基锂 、 双(三甲基硅烷基)氨基钾 、 二异丁基氢化铝 、 甲基磺酰氯 、 三乙胺 、 二异丙胺 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 四氯化碳 、 正己烷 、 二氯甲烷 、 环己烷 、 1,2-二氯乙烷 、 丙酮 、 甲苯 、 叔丁醇 为溶剂， -78.0~20.0 ℃ 、268.9 kPa 条件下， 反应 215.75h， 生成 (1R,3aR,4R,5S,9bR)-4,5-bis(tert-butyldimethylsilanyloxy)-1-isopropyl-6-methoxy-3a,8-dimethyl-2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalene
  参考文献：
  名称：

  Clive, Derrick L J; Wang, Jian, Journal of Organic Chemistry, 2004, vol. 69, # 8, p. 2773 - 2784

  摘要：

  DOI：
• 作为产物：
  描述：

  2-bromo-6-methoxy-p-toluidine 在 盐酸 、 异丙基氯化镁 、 sodium nitrite 作用下， 以 水 、 甲苯 、 乙腈 为溶剂， 反应 4.41h， 生成 2-bromo-6-methoxy-4-methylbenzaldehyde
  参考文献：
  名称：

  Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group

  摘要：

  Members of the catechol diether class are highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). The most active compounds yield EC50 values below 0.5 nM in assays using human T-cells infected by wild-type HIV-1. However, these compounds such as rilpivirine, the most recently FDA-approved NNRTI, bear a cyanovinylphenyl (CVP) group. This is an uncommon substructure in drugs that gives reactivity concerns. In the present work, computer simulations were used to design bicyclic replacements for the CVP group. The predicted viability of a 2-cyanoindolizinyl alternative was confirmed experimentally and provided compounds with 0.4 nM activity against the wild-type virus. The compounds also performed well with EC50 values of 10 nM against the challenging HIV-1 variant that contains the Lys103Asn/Tyr181Cys double mutation in the RT enzyme. Indolyl and benzofuranyl analogues were also investigated; the most potent compounds in these cases have EC50 values toward wild-type HIV-1 near 10 nM and high-nanomolar activities toward the double-variant. The structural expectations from the modeling were much enhanced by obtaining an X-ray crystal structure at 2.88 Å resolution for the complex of the parent 2-cyanoindolizine 10b and HIV-1 RT. The aqueous solubilities of the most potent indolizine analogues were also measured to be ~40 μg/mL, which is similar to that for the approved drug efavirenz and ~1000-fold greater than for rilpivirine.

  DOI：

  10.1021/ja408917n

文献信息

• COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS
  申请人：YALE UNIVERSITY

  公开号：US20150105351A1

  公开（公告）日：2015-04-16

  The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.

  本发明涉及新型纳摩尔和皮摩尔HIV逆转录酶抑制剂，以及由此制备的药物组合物和用于抑制逆转录酶和治疗HIV感染的方法，特别包括对HIV-1和HIV-2的耐药菌株以及作为HIV感染后果发生的次生疾病状态和/或条件。
• Synthesis of Optically Pure (+)-Puraquinonic Acid and Assignment of Absolute Configuration to Natural (−)-Puraquinonic Acid. Use of Radical Cyclization for Asymmetric Generation of a Quaternary Center
  作者：Derrick L. J. Clive、Maolin Yu、Mousumi Sannigrahi

  DOI：10.1021/jo040115b

  日期：2004.6.1

  key reactions used to make optically pure allylic alcohol 40. Radical cyclization of the derived Stork bromo acetals gives lactol ethers 43, which were degraded to generate a quaternary center carrying a methoxycarboxyl group (44 → 47). Compound 47 was converted into (+)-puraquinonic acid; and comparison with a natural sample established that the configuration of the natural compound is 2R (1).

  醛31和酰亚胺32之间的不对称羟醛反应，随后在随后的阶段进行闭环复分解（38 → 40），是用于制备光学纯烯丙基醇40的关键反应。衍生的鹳溴代乙缩醛的自由基环化产生乳醇醚43，其被降解以生成带有甲氧基羧基（44 → 47）的季中心。将化合物47转化为（+）-嘌呤醌酸；并与天然样品进行比较，确定天然化合物的构型为2 R（1）。
• Construction of quaternary centres for natural polycycles: The Pauson–Khand approach
  作者：Eduardo Arnáiz、Jaime Blanco-Urgoiti、Delbrin Abdi、Gema Domínguez、Javier Pérez Castells

  DOI：10.1016/j.jorganchem.2008.04.023

  日期：2008.7

  Construction of quaternary carbons is a challenge in PK chemistry, with few precedents in the literature. Starting from suitable functionalized enynes including an aromatic ring that templates the reaction, polycyclic ketones are obtained with a quaternary carbon. Special reaction conditions are necessary including the use of molecular sieves and co-catalysis with rhodium complexes jointly with cobalt

  季碳的构建是PK化学的一个挑战，文献中尚无先例。从合适的官能化的炔烃开始，该炔烃包括使反应模板化的芳族环，并用季碳获得多环酮。特殊的反应条件是必要的，包括使用分子筛以及与铑配合物和羰基钴共同催化。获得的产物是合成各种天然产物（如Hamigeran家族和甾体生物碱Conessine）的中间体。
• TRISUBSTITUTED BORON-CONTAINING MOLECULES
  申请人：Xia Yi

  公开号：US20110136763A1

  公开（公告）日：2011-06-09

  This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.

  这项发明主要涉及3,4,6-三取代苯并硼酸酯化合物及其用于治疗细菌感染的用途。
• Synthesis of 3-substituted indazoles and benzoisoxazoles via Pd-catalyzed cyclization reactions: application to the synthesis of nigellicine
  作者：Kiyofumi Inamoto、Mika Katsuno、Takashi Yoshino、Yukari Arai、Kou Hiroya、Takao Sakamoto

  DOI：10.1016/j.tet.2007.01.010

  日期：2007.3

  Syntheses of 3-substituted indazoles and benzoisoxazoles were efficiently accomplished with the aid of Pd-catalyzed intramolecular carbon-nitrogen and carbon-oxygen bond formations. The catalyst system described herein allows the cyclization to proceed under very mild conditions and thus could be applied to a wide range of substrates with acid- or base-sensitive functional groups. A total synthesis for the indazole ring-containing natural product nigellicine is also described. (c) 2007 Elsevier Ltd. All rights reserved.